PharmaEssentia saw its October revenue surge 67% to 910 million yuan ($125 million) as demand for its blood cancer drug Ropeg gained traction in the US and Japanese markets.
The Taiwanese drugmaker’s revenue for the first ten months reached 7.59 billion yuan ($1.04 billion), marking an 89.4% increase from the previous year. The company recently launched a home delivery service in Japan to boost accessibility for patients.
PharmaEssentia awaits FDA review of Ropeg’s pen syringe application, with a decision expected by January 10, 2025. The company is expanding its rare disease portfolio with ongoing Phase III trials for essential thrombocythemia and primary myelofibrosis treatments.
In a push to diversify its pipeline, Yaohua has filed an application with Taiwan’s Food and Drug Administration to begin Phase I trials for its TCR-T cell therapy targeting terminal solid tumors. This marks the company’s first venture into the growing field of cellular immunotherapy.
The positive sales trajectory comes as PharmaEssentia strengthens its US presence with a new leadership team focused on expanding market coverage for Ropeg.
